Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma

Sponsor
MGH Institute of Health Professions (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05700747
Collaborator
(none)
20
1
1
12.9
1.6

Study Details

Study Description

Brief Summary

The purpose of this study is to explore whether a structured program can help reduce the challenges of decreased physical functioning and quality of life for participants with multiple myeloma by providing a customized exercise program and fostering engagement in meaningful activities.

The name of the study intervention involved in this study is:

Health Through Activity (HTA) (six-session, rehabilitation exercise regimen)

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Health Through Activity
N/A

Detailed Description

The goal of this single arm, pilot study of the Health Through Activity (HTA) rehabilitation intervention for people living with multiple myeloma is to determine if investigators can feasibly deliver the program out of the IMPACT Practice Center at the MGH Institute for Health Professions.

  • The six-session 'Health Through Activity' program provides a customized exercise plan and encourages engagement in activities to reduce disability and improve quality of life.

  • Study procedures including screening for eligibility, in-clinic visits, questionnaires, and surveys.

  • Participation in this research study is expected to last up to 4 months.

It is expected that up to 20 people will take part in this research study.

An internal grant from the Massachusetts General Hospital Institute of Health Professions is providing equipment and staffing for this study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Feb 28, 2024
Anticipated Study Completion Date :
Feb 28, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Health Through Activity (HTA) Intervention

Participants will undergo study procedures as outlined: Complete a baseline survey regarding activity level and quality of life. Attend 6 weekly study visits at the MGH Institute of Health Professions IMPACT Practice Center. Attend final study visit and complete the Satisfaction survey and an individual, semi-structured interview with site staff to supply feedback about the program. After six weeks, complete the Satisfaction survey again.

Behavioral: Health Through Activity
Six, weekly, customized sessions with licensed physical and occupational therapists.

Outcome Measures

Primary Outcome Measures

  1. Rate of Participant Enrollment [At screening]

    Number participants enrolled / Number screened positive & eligible. A rate of at least 75% will indicate feasibility.

  2. Assessment Completion Rate [Up to 4 months]

    Defined as the number of participants completing each of the three study assessments to number of participants enrolled. A completion rate of 85% will indicate feasibility.

  3. Screening Rate [Up to 4 months]

    Number patients screened/ Number patients identified as potentially eligible. Screening rate of at least 75% will indicate feasibility

  4. Eligibility Rate [Up to 4 months]

    Number patients screening positive & eligible / Number screened. Eligibility rate is influenced by how many people in the clinical population are experiencing disability. Based on our pilot study, expected rate to be at least 35%.

Secondary Outcome Measures

  1. Intervention Completion Rate [Up to 3 months]

    Defined as at least 75% of participants complete all six sessions of Health Through Activity (HTA) and if the mean number of sessions is greater than or equal to 4.

  2. Participant Satisfaction [Up to 4 months]

    Assessed by the Satisfaction survey which is a 7-item survey that is rated on a 5-point Likert scale. Any item on the Satisfaction survey that generates a mean score of < 4 will trigger consideration of modification to the HTA program.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

-≥18 years of age

  • Diagnosed with multiple myeloma currently receiving maintenance therapy,

  • Experiencing disability as indicated by an answer of "yes" to the question "Do health problems interfere with your ability to carry out your social or day to day activities?"

Exclusion Criteria:
  • Bone pain that is either a) new onset or increased in the past month or b) uncontrolled i.e., in the patient's estimation the bone pain "greatly interferes with daily activities"

  • History of fracture in the past 12 months without fixation, or

  • Any injury or medical condition that would prohibit being able to safely perform exercise as indicated by the Physical Activity Readiness Questionnaire[29] (i.e., atrial fibrillation, chest pain or angina, uncontrolled high blood pressure or hypertension, loss of balance due to dizziness in the past 12 months, or loss of consciousness in the past 12 months).

  • We will also exclude individuals with moderate or worse cognitive impairment as indicated by a score of 3 or less on the Callahan six item cognitive screening tool.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Cancer Center Boston Massachusetts United States 02215

Sponsors and Collaborators

  • MGH Institute of Health Professions

Investigators

  • Principal Investigator: Kathleen Lyons, ScD, OTR/L, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kathleen Lyons, ScD, OTR/L, Principal Investigator, MGH Institute of Health Professions
ClinicalTrials.gov Identifier:
NCT05700747
Other Study ID Numbers:
  • 22-437
First Posted:
Jan 26, 2023
Last Update Posted:
Jan 26, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kathleen Lyons, ScD, OTR/L, Principal Investigator, MGH Institute of Health Professions
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2023